C-Met Mutated Non-Small Cell Lung Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)

Posted on
by

C-Met Mutated Non-Small Cell Lung Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)

DelveInsight’s, “C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Pipeline Insight 2023” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) pipeline landscape. It covers the C-Met Mutated Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the C-Met Mutated Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the C-Met Mutated Non-Small Cell Lung Cancer Pipeline Report

  • DelveInsight’s C-Met Mutated Non-Small Cell Lung Cancer pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for C-Met Mutated Non-Small Cell Lung Cancer treatment.
  • The leading companies working in the C-Met Mutated Non-Small Cell Lung Cancer Market include Novartis, Apollomics Inc., Abbvie, Janssen Research and Development, and others.
  • Promising C-Met Mutated Non-Small Cell Lung Cancer Pipeline Therapies in the various stages of development include INC280, Gefitinib, Glumetinib, APL-101 Oral Capsules, ARQ 197, and others.
  • October 2023: Apollomics Inc. announced a study of Phase 2 clinical trials for APL-101 Oral Capsules. Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors.

 

Request a sample and discover the recent advances in C-Met Mutated Non-Small Cell Lung Cancer Treatment Drugs @ C-Met Mutated Non-Small Cell Lung Cancer Pipeline Report

 

In the C-Met Mutated Non-Small Cell Lung Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

C-Met Mutated Non-Small Cell Lung Cancer Overview

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) is characterized by over-expression of C-Met tyrosine kinase receptor which is normally expressed by epithelial cells. C-Met stimulation induces phosphorylation of some specific tyrosine residues such as (Y1003-Y1313-Y1230/1234/1235-Y1349-Y1365) thereby activating multiple downstream signaling pathways including RAS/ERK, PI3K/AKT, and cSRC kinase pathways.

 

Find out more about C-Met Mutated Non-Small Cell Lung Cancer Therapeutics Assessment @ C-Met Mutated Non-Small Cell Lung Cancer Preclinical and Discovery Stage Products

 

C-Met Mutated Non-Small Cell Lung Cancer Emerging Drugs Profile

  • EGF-816 (Nazartinib): Novartis Oncology
  • APL 101 (Bozitinib): Appolomics Inc.

 

C-Met Mutated Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment

There are approx. 5+ key companies which are developing the therapies for C-Met Mutated Non-small Cell Lung Cancer (NSCLC). The C-Met Mutated Non-Small Cell Lung Cancer companies which have their C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) drug candidates in the mid to advanced stage, i.e. phase III include, Novartis Oncology and others.

 

DelveInsight’s C-Met Mutated Non-Small Cell Lung Cancer Pipeline Report covers around 5+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II and Phase I/II)
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Molecule Type

 

C-Met Mutated Non-Small Cell Lung Cancer Pipeline Products have been categorized under various Molecule types such as

  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type

 

Learn more about the emerging C-Met Mutated Non-Small Cell Lung Cancer Pipeline Therapies @ C-Met Mutated Non-Small Cell Lung Cancer Clinical Trials Assessment

 

Scope of the C-Met Mutated Non-Small Cell Lung Cancer Pipeline Report

  • Coverage- Global
  • C-Met Mutated Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • C-Met Mutated Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • C-Met Mutated Non-Small Cell Lung Cancer Companies- Novartis, Apollomics Inc., Abbvie, Janssen Research and Development, and others.
  • C-Met Mutated Non-Small Cell Lung Cancer Pipeline Therapies- INC280, Gefitinib, Glumetinib, APL-101 Oral Capsules, ARQ 197, and others.

 

Dive deep into rich insights for new drugs for C-Met Mutated Non-Small Cell Lung Cancer Treatment, Visit @ C-Met Mutated Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. C-Met Mutated Non-Small Cell Lung Cancer (NSCLC): Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Collaboration Deals
  9. Late Stage Products (Phase III)
  10. EGF 816 (Nazartinib): Novartis
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. APL 101 (Bozitinib): Apollomics Inc.
  14. Drug profiles in the detailed report…..
  15. Pre-clinical and Discovery Stage Products
  16. Drug profiles in the detailed report…..
  17. Inactive Products
  18. C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Key Companies
  19. C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Key Products
  20. C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)- Unmet Needs
  21. C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)- Market Drivers and Barriers
  22. C-Met Mutated Non-Small Cell Lung Cancer (NSCLC)- Future Perspectives and Conclusion
  23. C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Analyst Views
  24. C-Met Mutated Non-Small Cell Lung Cancer (NSCLC) Key Companies
  25. Appendix

 

For further information on the C-Met Mutated Non-Small Cell Lung Cancer Pipeline therapeutics, reach out to C-Met Mutated Non-Small Cell Lung Cancer Unmet Needs and Analyst Views

 

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services